Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORAKLE: lorlatinib after first-line alectinib or brigatinib failure in advanced ALK-positive NSCLC
2019-002230-37Phase 2Completed
- Sponsor
- IFCT
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC) and ALK-positive non-small cell lung cancer, sponsored by IFCT. Primary endpoint: Objective response rate at 6 weeks. Started Jul 2019; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on 2019-002230-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002230-37.